Sources: EvolutionaryScale, founded by members of Meta's recently axed protein-folding team to build LLMs for biology, raised a $40M+ seed at a $200M valuation
Forbes : X: @_iainmartin and @kenrickcai X: Iain Martin / @_iainmartin : Meta shuttered it's AI project focused on protein-folding in April. Now that team have raised $40m to build new biological LLMs that could help develop everything from cancer-fighting programmable cells to organisms that clean up toxic waste https://www.forbes.com/... @kenrickcai Kenrick Cai / @kenrickcai : Scoop: Researchers from Meta AI's recently axed protein-folding team have started a new company to keep building a LLM for biology. EvolutionaryScale raised $40M+ from Lux Capital, per sources. From @_IainMartin and I, with details from a pitch doc: https://www.forbes.com/...
Context & Ripple Effects
Meta’s reported spring shutdown of ESMFold created the immediate talent and research break that led former team members to form EvolutionaryScale. The seed round gives that work an independent commercial path rather than leaving it inside Meta’s shift toward product-focused AI priorities.
The company’s later release of ESM3 models for protein engineering shows the initial financing was followed by a product push. Related coverage of Latent Labs and Lila Sciences also places the company within a growing group trying to apply foundation-model methods to scientific discovery.
First-order effects
- EvolutionaryScale gains more than $40 million in reported seed financing to continue developing biology-focused language models outside Meta.
- Meta loses direct ownership of a specialized protein-modeling team it had disbanded, while Lux Capital becomes an early backer of the spinout.
Second-order effects
- The round gives other biology-AI startups and research teams a clearer venture-financing benchmark, increasing pressure to show that model development can translate into useful scientific tools.
- EvolutionaryScale can compete more directly for the researchers and compute needed for protein-model development, rather than relying on a large-platform employer.
Third-order effects
- If teams displaced by large labs can repeatedly secure standalone funding, advanced scientific-model research may increasingly move into venture-backed specialist companies rather than remain internal corporate research.
- The pattern would make capital endurance a central differentiator in biology AI: model builders will need to sustain expensive research long enough to demonstrate real-world utility.
The trend: This is one early example of frontier AI research teams leaving platform companies to build independently funded, domain-specific model labs.